Cantor Fitzgerald Reiterates Overweight on Keros Therapeutics
Piper Sandler Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $105
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
A Quick Look at Today's Ratings for Keros Therapeutics(KROS.US), With a Forecast Between $84 to $105
Keros Therapeutics Third Quarter 2024 Earnings: US$1.41 Loss per Share (Vs US$1.33 Loss in 3Q 2023)
HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target